OIA invests in Indian pharma firm, targets insulin plant in Oman
Muscat - In its efforts to attain self-sufficiency in pharmaceutical manufacturing, Oman Investment Authority (OIA) has announced an investment in BioGenomics, a developer of biosimilar drugs with a focus on diabetic therapy.